Ryuichi Kato

Muroran, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Risk Assessment of Non-Urinary Tract Recurrence After Radical Nephroureterectomy Based on CheckMate 274 Trial Eligibility: A Multicenter Retrospective Study.

Risk Assessment of Non-Urinary Tract Recurrence After Radical Nephroureterectomy Based on CheckMate 274 Trial Eligibility: A Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: December 12, 2025

A Case of Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia (PGAD/GPD) Improved with Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

A Case of Persistent Genital Arousal Disorder/Genito-Pelvic Dysesthesia (PGAD/GPD) Improved with Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: November 06, 2025

Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit.

Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit.

Journal: Cancers

Published: October 08, 2025

Clinical Outcomes of Untreated Recurrence After Radical Surgery for Upper Urinary Tract Carcinoma: A Multicenter Retrospective Study.

Clinical Outcomes of Untreated Recurrence After Radical Surgery for Upper Urinary Tract Carcinoma: A Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 20, 2025

The efficacy of metastasis-directed external beam radiotherapy for castration-resistant prostate cancer: A retrospective multicenter study.

The efficacy of metastasis-directed external beam radiotherapy for castration-resistant prostate cancer: A retrospective multicenter study.

Journal: Current urology

Published: December 03, 2024

Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Non-Muscle Invasive Bladder Cancer.

Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Non-Muscle Invasive Bladder Cancer.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: November 12, 2024

Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study.

Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study.

Journal: Journal of geriatric oncology

Published: March 12, 2024

Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.

Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.

Journal: Anticancer research

Published: November 15, 2023

Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.

Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.

Journal: World journal of urology

Published: August 14, 2023

Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.

Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: May 15, 2023

Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.

Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: November 23, 2021

Fever after Gemcitabine Administration is a Poor Prognostic Factor in Patients with Metastatic Urothelial Carcinoma : Multicenter Retrospective Study

Fever after Gemcitabine Administration is a Poor Prognostic Factor in Patients with Metastatic Urothelial Carcinoma : Multicenter Retrospective Study

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: June 14, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026